Principal Software Engineer in Test

eClinical Solutions turns Clinical Data intelligence into action at ENGAGE 2026. Press Releases Released: October 8, 2026 Leading industry experts will come together for multi-day conference to discuss how advancements in AI-driven automation, agentic AI, and data analytics will accelerate clinical trials October 8, 2026, BOSTON - eClinical Solutions LLC, a global provider of digital clinical software and services, will convene global technology and biopharma leaders October 12-14 for its eighth annual client and partner conference, ENGAGE 2026. The company will host over 250 attendees at W Philadelphia, including representatives from over 75 life science organizations such as GSK, Moderna, Bayer, Takeda, Daiichi-Sankyo, Vertex, Eisai, ICON, and industry partner corporate sponsors including PwC and Cognizant. "As AI becomes more capable, the question for clinical development is how to make it useful in work where context matters and decisions carry consequences," said Raj Indupuri, CEO and co-founder of eClinical Solutions. "That requires going beyond technology to incorporate the expertise of the people conducting the research. Our eighth annual ENGAGE event brings those people together to share what is working and help shape what comes next." Day 1 Agenda Highlights Raj Indupuri will give a CEO address discussing how connected data, study context, and human judgment can turn rapidly improving AI into clinical decisions people can trust. eClinical Solutions' Chief Product Officer, Nathan Johnson, will illustrate a future "day in the life" of clinical teams working with AI, showing how clinical data intelligence can inform their decisions and actions. Dr. Elin Haf Davies will take the stage for the keynote address. A former children's nurse with a PhD in Neurometabolics, Dr. Davies has spent her career advancing treatments for rare diseases, including working in drug development, advising the European Medicines Agency, and founding digital health company Aparito. She is the first Welsh woman to row across the Atlantic and was on the first all-woman team to row across the Indian Ocean. She will share lessons in resilience, adaptability, and embracing uncertainty, exploring how leaders can lean into change, inspire innovation, and turn ideas into action. Also on day 1, Lauren Katzenstein and John Hirschman from Merck will share the company's medical monitoring journey with eClinical Solution's clinical data intelligence platform, elluminate. Later in the day, Parexel's Kenneth Lima Ganse and Swatin Shetty will present on the company's experience using elluminate to turn data into insight. Their presentation will include examples of how Parexel's experience implementing elluminate helps inform and strengthen platform innovation. The company will host mainstage discussions and interactive breakout sessions focused on advancing integrated and risk-based approaches to data review and management, along with risk-based quality management (RBQM) implementation, integration, and adoption with elluminate. As sponsors adapt to ICH E6(R3), effective RBQM requires organizations to integrate quality considerations into trial design and execution. Other session topics will address data ingestion and transformation workflows, and streamlining risk-based data management workflows with an integrated data review plan (IDRP). Additional speakers on day 1 will include Alex Crawford from Jazz Pharmaceuticals, Stijn Rogiers and Jasmine Kestemont from argenx, Jonathan Rowe from ZS, and Sean McNiff of Dyne Therapeutics. eClinical's Bob Arnesen, Vera Pomerantseva, Les Jordan, Sam Anwar, Meredith Bell, Nick Bartolone, Alicia Asgari, Jason Konn, and Raghu Cilukha will also present, alongside event emcee Dawn Kaminski. Day 2 Agenda Highlights Sarah Clark from AstraZeneca, Michael Underhill from Astellas, and Renu Shukla from Johnson & Johnson will join eClinical's Gina Wood to explore the human and operational impact of AI in clinical research during the panel "How Work Happens Now: Rethinking Clinical Data Process and Expertise in the Age of AI." While industry conversation focuses on new models, agents, and use cases, the panel will tackle the harder questions around what AI means for the people, processes, and expertise behind the work. Ian Shafer and Mike Kelley from PwC will highlight the power of turning signals into action when technology can break down silos and dynamically connect RBQM with R&D Ops. In the afternoon Chief Delivery Officer, Biometrics Services, Katrina Rice, together with eClinical's Grant Williamson, Diane Lacroix, and Demi Niforos, will review how the eClinical Solutions Biometrics Services team uses elluminate, incorporates AI into workflows, and operationalizes the clinical data intelligence platform for successful data delivery outcomes. Additional sessions on day 2 will focus on clinical data platform change management and adoption, data review AI use cases and results, and cross-functional collaboration via elluminate. Speakers will include Peter Bayer of Ascendis Pharma and Crystal Matthews-Barron of Karyopharm Therapeutics, plus eClinical's Yuliya Cashman-Kiperberg and Jaclyn Clark. About eClinical Solutions LLC. eClinical Solutions' industry-leading clinical data intelligence platform, elluminate(R), and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations develop tomorrow's breakthroughs with today's resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of the 2026 Top Workplace Award: Remote Work, the 2026 Top Workplaces Culture Excellence Awards: Purpose & Values and Professional Development, and Great Place To Work(R) India Certification(TM). Learn more at https://www.eclinicalsol.com/ and follow eClinical Solutions on LinkedIn.

The Gartner(R) Hype Cycle(TM) for Life Science R&D, 2026: what tech is worth the Hype? Published: August 5, 2026 Clinical development teams have no shortage of technologies to choose from. Across the market, solutions promise to improve trial efficiency, strengthen oversight, reduce costs, and help bring therapies to patients faster. But as the pace of technology innovation increases, the question of which technologies to invest in becomes difficult to answer. This year's Gartner(R) Hype Cycle(TM) for Life Science R&D attempts to discover which of these latest technologies are worth the hype. Designed to help life science leaders assess the potential value, maturity, and adoption timelines of the latest tech, The Gartner(R) Hype Cycle(TM) for Life Science R&D, 2026 evaluates more than 30 emerging and maturing technologies across discovery, clinical development, laboratory operations, regulatory affairs, and quality management. For clinical trial organizations, three technologies listed in the Hype Cycle(TM) stand out to eClinical Solutions LLC. * Clinical Data Analytics Platforms * Risk-Based Quality Management * GenAI Clinical Intelligence Below, eClinical Solutions LLC explore why these technologies are especially relevant to clinical development, and what organizations should consider as they evaluate their adoption strategies. Clinical Data Analytics Platforms. Clinical trials generate growing volumes of clinical, operational, safety, and patient data across an expanding ecosystem of systems and partners. Yet much of that information remains fragmented, making it difficult for teams to gain a timely and complete view of trial performance. According to Gartner, clinical data analytics platforms, "unify clinical data management, operational analytics and data science workflows on a lakehouse architecture, replacing traditional data warehouses and point analytics tools. They augment existing solutions involved in intaking, processing and managing clinical and operational data from source systems and enable end-user analytics point solutions that support trial operations." The united data from multiple trial sources supports activities such as clinical review, operational analytics, data mapping, visualization, statistical analysis, and AI-enabled workflows. eClinical Solutions LLC also see Gartner identify several barriers to adoption, including continued reliance on paper-based processes, legacy clinical data warehouses, unclear return on replacement investments, and the operational changes required to introduce more integrated ways of working. What does this mean for clinical trial organizations? CDAPs are set to improve transparency, break down data silos, and enable impactful, more informed decision. But value of your analytics solution depends on the data beneath it. Organizations assessing clinical data analytics platforms should consider how effectively a solution can connect clinical and operational data, support existing review processes, and establish a scalable foundation for future analytics and AI initiatives. Note: Gartner listed eClinical Solutions as a Sample Vendor in the Clinical Data Analytics Platform category. Explore the elluminate(R) Clinical Data Intelligence Platform here. Risk-Based Quality Management. Risk-based approaches are now an established part of clinical trial strategy and regulatory guidance. However, successfully putting Risk-Based Quality Management into practice remains a challenge for many organizations. Gartner describes RBQM as an approach that applies risk assessment and quality management across clinical trials and says, "These tools allow for trial operations teams to monitor trials, investigator sites and patient data based on evaluated risk to patient safety and trial outcomes." Rather than relying on 100% source data verification, RBQM helps teams direct monitoring and quality activities toward the areas presenting the greatest risk to patient safety or trial outcomes. eClinical Solutions LLC see that The report points to continued regulatory momentum - including the adoption of ICH E6(R3) - as a driver of RBQM technology. It also identifies the growing interest in AI-assisted risk review and centralized monitoring. Despite these factors driving RBQM technology innovation and adoption, traditional monitoring practices, siloed applications, cultural resistance, and limited confidence in data integrity and auditability continue to slow adoption. Effective RBQM requires more than individual risk indicators or dashboards. When evaluation RBQM solutions, organizations should consider how technology supports the full risk-management process - from risk assessment and review planning through centralized monitoring, issue management, mitigation, and ongoing oversight. Note: Gartner listed eClinical Solutions as a Sample Vendor in the Risk-Based Quality Management category. Explore elluminate(R) RBQM here. GenAI Clinical Intelligence. Generative AI has attracted significant attention across the life sciences, but the Gartner description of GenAI clinical intelligence is more specific than a general-purpose chatbot. Gartner defines the technology as, "an AI conversational assistant that provides an intelligence layer for e-clinical solutions, leveraging e-clinical content stores and context-specific protocols, SOPs, training resources, runbooks, study plans, and other information to provide responses to user queries." These assistants can provide users with relevant information, insights, alerts, and workflow support within the clinical development environment. Though the potential is significant, Gartner classifies GenAI clinical intelligence as emerging, with current market penetration of only 1% to 5%. Trusted content and data architectures, carefully selected use cases, human oversight, governance, validation, and protection against inaccurate outputs will all be important to responsible adoption. Clinical AI will be most valuable when it is grounded in trusted study data, documentation, and workflows. As organizations evaluate AI capabilities, they should consider not only what an assistant can generate, but also how its responses are governed, verified, and connected to the work clinical teams already perform. Explore the Gartner Hype Cycle for Life Science R&D, 2026. Clinical development leaders face an expanding field of technology choices, each competing for investment and attention. The Gartner Hype Cycle for Life Science R&D, 2026 provides an independent view of the technologies shaping the industry, their potential business value, and their expected time to mainstream adoption. Download the full report to explore the Gartner analysis of clinical data analytics platforms, Risk-Based Quality Management, GenAI clinical intelligence, and the other technologies influencing the future of life science R&D. Gartner Hype Cycle for Life Science R&D, 2026, By Reuben Harwood, Jeff Smith 12 June 2026 Gartner and Hype Cycle is a trademark of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.